Subcutaneous versus intravenous ultra-low-dose rituximab in rheumatoid arthritis: a randomized controlled PK-PD non-inferiority trial.

Bovens PMET, van der Togt CJT, den Broeder N, Verhoef LM, van der Maas A, Hobo W, Bloem K, Ter Heine R, van den Bemt BJF, den Broeder AA

Open source

DOI: 10.1093/rheumatology/keag420
Published: 2026 Sep 1
Container: Rheumatology (Oxford, England)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/rheumatology/keag420,
  title = {Subcutaneous versus intravenous ultra-low-dose rituximab in rheumatoid arthritis: a randomized controlled PK-PD non-inferiority trial.},
  author = {Bovens PMET and van der Togt CJT and den Broeder N and Verhoef LM and van der Maas A and Hobo W and Bloem K and Ter Heine R and van den Bemt BJF and den Broeder AA},
  year = {2026},
  journal = {Rheumatology (Oxford, England)},
  doi = {10.1093/rheumatology/keag420},
  url = {https://doi.org/10.1093/rheumatology/keag420}
}

RIS

TY  - JOUR
TI  - Subcutaneous versus intravenous ultra-low-dose rituximab in rheumatoid arthritis: a randomized controlled PK-PD non-inferiority trial.
AU  - Bovens PMET
AU  - van der Togt CJT
AU  - den Broeder N
AU  - Verhoef LM
AU  - van der Maas A
AU  - Hobo W
AU  - Bloem K
AU  - Ter Heine R
AU  - van den Bemt BJF
AU  - den Broeder AA
PY  - 2026
JO  - Rheumatology (Oxford, England)
DO  - 10.1093/rheumatology/keag420
UR  - https://doi.org/10.1093/rheumatology/keag420
ER  -

APA

PMET, B., CJT, V. D. T., N, D. B., LM, V., A, V. D. M., W, H., K, B., R, T. H., BJF, V. D. B., & AA, D. B. (2026). Subcutaneous versus intravenous ultra-low-dose rituximab in rheumatoid arthritis: a randomized controlled PK-PD non-inferiority trial.. Rheumatology (Oxford, England). https://doi.org/10.1093/rheumatology/keag420

Source records

pubmed · retrieved 2026-09-26T18:58:18.657Z